RxDoctor Payments Data

Stephen Bowser, MD

Cardiovascular Disease · Greensburg, PANPI 1598737355

Payments from drug & device makers

$4,058in general payments, 2019–2025

Across 158 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novartis$618
  • Johnson & Johnson$502
  • Innovation Technologies Inc$296
  • Pfizer$262
  • Amgen$251
  • plus $760 from 15 others

What the payments were for

  • Travel & lodging$98424%
  • Food & beverage$3,07576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,058 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$58,842
Medicare patients
567
Services billed
1,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$239,910
EntrestoSacubitril/Valsartan66$100,790
XareltoRivaroxaban49$56,167
BrilintaTicagrelor18$17,186
Metoprolol Succinate199$3,462
Atorvastatin Calcium207$3,379
Diltiazem 24hr Er (Cd)Diltiazem Hcl41$2,342
Carvedilol120$1,453
Losartan Potassium62$1,329
Metoprolol Tartrate173$1,292
Rosuvastatin Calcium86$1,198
Lisinopril159$1,161
ClopidogrelClopidogrel Bisulfate64$960
Isosorbide Mononitrate ErIsosorbide Mononitrate58$843
Bisoprolol Fumarate15$828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$262$239,910218 claims
NovartisEntresto$618$100,79066 claims
Johnson & JohnsonXarelto$502$56,16749 claims
AstraZenecaBrilinta$60$17,18618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →